Prospective Multicenter Study to Confirm the Performance of the Renzan Stent in Treatment of SFA/POP Artery Disease

NCT ID: NCT04546477

Last Updated: 2023-08-25

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 135 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-07-30
• Study Completion Date: 2026-06-30

Brief Summary

The primary objective of this study is to confirm the safety and efficacy of the RenzanTM Peripheral Stent System when used for treatment of superficial femoral (SFA) and/or popliteal (POP) artery disease.

This trial plans to include 135 patients in (up to) 10 locations around in Europe.

Detailed Description

PRIZER Study is a prospective, multicenter, post-market, single arm study with plan to include approximately 135 patients eligible to be treated with RenzanTM Peripheral Stent System stratified in 2 groups: 90 FEM-POP patients (From superficial femoral Artery to the Proximal edge of patella) and 45 Isolated POP patients (From Hunter's canal to the Origin of anterior tibial artery).

The sponsor will work in accordance with standard operating procedures (SOP) and the Monitoring Plan in order to ensure adherence to the CIP and applicable regulations at the investigational sites.

The Monitoring Plan is built according to a risk-based monitoring approach and describes the level of source data verification to be performed by the monitors.

Risk-based monitoring approach uses all available means to supervise the trial (central monitoring, remote monitoring and on-site monitoring), focusing in critical data points and issues ensuring that adequate monitoring (central, remote and on-site) at each site is completed to ensure protection of the rights and safety of the subjects and the quality and integrity of the data collected and submitted.

The sponsor shall provide training and the necessary guidelines to assist each investigational site on the data collection in the eCRF. Each site is responsible to report the available data requested by the CIP. In order to ensure data quality and avoid missing information in the eCRF, edit checks are designed during database development. In addition, Sponsor's CRA and Data Management team will be responsible to review the data and raise queries accordingly into the eCRF. An audit trail logging all data entered and edited is available within the EDC system. All source documents are maintained in the hospital files ready for inspection by the Sponsor and regulatory authorities upon request. The Sponsor will inform the investigator of the time period for retaining these records as per applicable regulatory requirements.

Conditions

Superficial Femoral Artery Disease; Popliteal Artery Disease

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Single Arm

135 patients stratified into 2 groups:

• FEM-POP patients: SFA-P1
• Isolated POP Patients: P1, P2, P3 only

It is expected the majority of enrolled patients to be FEM-POP category. In case sufficient Isolated POP patients are enrolled, a sub-analysis will be performed on this group of patients.

Group Type: OTHER

Stent implantation

Intervention Type: DEVICE

Procedure can be conducted via either contralateral or antegrade approach. After a successful target lesion crossing, predilate the lesion using either plain old balloon angioplasty (POBA) or (if necessary) any available specialty balloon. The inflated diameter of the balloon should approximate the diameter of the vessel just distal to the lesion. Proper vessel preparation should achieve diameter of 1:1 to healthy vessel (with ≤20% residual stenosis, as per operator's assessment). Adjunctive debulking devices are prohibited.

Final stent selection should be confirmed after a proper vessel preparation, considering the reference vessel diameter (RVD) for the optimal 1:1 stent-to-vessel sizing. The implanted dual layer length would encompass the entire lesion with the micromesh, covering it from healthy to healthy tissue. Post-dilatation of the stent for more optimal placement may be done at operator's discretion, using standard angioplasty with uncoated balloon.

Interventions

Stent implantation

Procedure can be conducted via either contralateral or antegrade approach. After a successful target lesion crossing, predilate the lesion using either plain old balloon angioplasty (POBA) or (if necessary) any available specialty balloon. The inflated diameter of the balloon should approximate the diameter of the vessel just distal to the lesion. Proper vessel preparation should achieve diameter of 1:1 to healthy vessel (with ≤20% residual stenosis, as per operator's assessment). Adjunctive debulking devices are prohibited.

Final stent selection should be confirmed after a proper vessel preparation, considering the reference vessel diameter (RVD) for the optimal 1:1 stent-to-vessel sizing. The implanted dual layer length would encompass the entire lesion with the micromesh, covering it from healthy to healthy tissue. Post-dilatation of the stent for more optimal placement may be done at operator's discretion, using standard angioplasty with uncoated balloon.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Age ≥18 years.

2. Subject must provide written informed consent prior to the treatment of the target lesion.

3. Subject must be willing to comply with the specified follow-up evaluation schedule.

4. Subject with Rutherford-Becker clinical classification category 2 to 5, with a resting ankle-brachial index (ABI) ≤ 0.9.

5. A superficial femoral and/or popliteal artery lesion with > 50% stenosis or total occlusion.

6. Stenotic or occluded lesion(s) within the same vessel (one long or multiple serial lesions treatable with one stent) ≥ 40 mm and ≤ 140 mm in length, with reference vessel diameter (RVD) ≥ 4.0 mm and ≤ 7.0 mm by visual assessment.

7. A patent inflow artery free from significant lesion (≥50% stenosis) as confirmed by angiography (treatment of target lesion acceptable after successful treatment of ipsilateral iliac lesions); Successful ipsilateral iliac artery treatment is defined as attainment of residual diameter stenosis ≤30% without death or major vascular complication, either with PTA or stenting.

8. The target lesion(s) can be successfully crossed with a guide wire and dilated up to 1:1 to healthy vessel (as per operator's assesment).

9. At least one patent native outflow artery (anterior or posterior tibial or peroneal) to the foot, free from significant (≥50%) stenosis (as confirmed by angiography), that has not previously been revascularized. The remaining outflow arteries requiring treatment during the same procedure may be treated only with uncoated devices and before the target lesion.

10. A subject with bilateral obstructive SFA disease is eligible for enrollment into the study. If a subject with bilateral disease is enrolled, the target limb will be selected at the Investigator's discretion, who may use the criteria of lesion length, percent stenosis, and/or calcification content. The contra-lateral procedure should not be done until at least 30 days after the index procedure; however, if contralateral treatment is performed prior to treatment of the target lesion it should be performed at least 1 day before the index procedure with uncoated devices only.

11. The subject is eligible for surgical repair, if necessary.

Exclusion Criteria

1. Subject has Rutherford-Becker classification category 6.

2. Treatment of lesions requiring the use of adjunctive debulking devices.

3. The use of drug-coated balloons at any step of the procedure.

4. Required stent placement via a popliteal approach.

5. Required stent placement across or within 0.5 cm of the superficial and profunda femoral artery bifurcation.

6. In-stent restenosis treatment or any other procedure which requires stent-in-stent placement to obtain patency.

7. Restenotic lesion that had previously been treated by atherectomy, laser or cryoplasty within 3 months of the index procedure.

8. Lesion with the length that would require stent overlap.

9. Required stent placement within 1 cm of a previously deployed stent.

10. Any significant vessel tortuosity or other parameters prohibiting access to the lesion and/or preventing the stent delivery.

11. Subject with coronary intervention performed less than 90 days prior to or planned within 30 days after the treatment of the target lesion.

12. Known allergies or intolerance to nitinol (nickel titanium), or contrast agent.

13. Any contraindication or known unresponsiveness to dual antiplatelet therapy (DAPT) or anticoagulation therapy.

14. Presence of acute thrombus prior to crossing the lesion.

15. Thrombolysis of the target vessel within 72 hours prior to the index procedure, where complete resolution of the thrombus was not achieved.

16. Thrombophlebitis or deep venous thrombus, within the previous 30 days.

17. Subject receiving dialysis within the previous 30 days.

18. Stroke within the previous 90 days.

19. Known or suspected active infection at the time of the procedure.

20. Subject is pregnant or of child bearing potential

21. Subject has life expectancy of less than 1 year.

22. Subject is participating in an investigational study that has not reached primary endpoint at the time of study screening.

23. Treatment of outflow arteries (anterior or posterior tibial or peroneal) following target lesion treatment (unless bailout).

24. In France: Vulnerable patients, patients deprived from liberty and patients with a physical or mental state altered by disease, age or disability which impacts their ability to defend their interests and for which protection measures are taken ("protected majors" as per French law: articles L1121-5, 6, 8 et L1122-1-3, du code de la santé publique)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Terumo Europe N.V.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Koen Deloose, Dr

Role: PRINCIPAL_INVESTIGATOR

AZ Sint-Blasius Dendermonde

Torsten Fuss, Dr

Role: PRINCIPAL_INVESTIGATOR

Elblandhospital Radebeul

Michael Lichtenberg, Dr

Role: PRINCIPAL_INVESTIGATOR

Karolinen-Hospital: Klinikum Arnsberg

Jérôme Brunet, Dr.

Role: PRINCIPAL_INVESTIGATOR

Clinique Rhône-Durance

Locations

AZ Sint-Blasius

Dendermonde, Oost-Vlaanderen, Belgium

Onze Lieve Vrouw (OLV) Ziekenhuis

Aalst, , Belgium

Imelda ziekenhuis

Bonheiden, , Belgium

Ziekenhuis Oost Limburg

Genk, , Belgium

Clinique Rhône-Durance

Avignon, , France

Hôpital Paris Saint-Joseph

Paris, , France

Clinique Saint Jean - Sud de France

Saint-Jean-de-Védas, , France

Klinikum Hochsauerland Karolinen-Hospital Hüsten

Arnsberg, , Germany

CCB MVZ Frankfurt und Main-Taunus GbR

Frankfurt, , Germany

Elblandklinikum Radebeul

Radebeul, , Germany

Diakonessenhuis

Utrecht, , Netherlands

Hospital Germans Trias i Pujol

Badalona, , Spain

Hospital Universitario Cruces

Bilbao, , Spain

Countries

Belgium; France; Germany; Netherlands; Spain

Other Identifiers

T134E5

Identifier Type: -

Identifier Source: org_study_id